WallStSmart

JBS N.V. (JBS)vsSRx Health Solutions Inc. (SRXH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

JBS N.V. generates 900749% more annual revenue ($84.15B vs $9.34M). JBS leads profitability with a 2.5% profit margin vs 0.0%. JBS earns a higher WallStSmart Score of 51/100 (C-).

JBS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 6.0Value: 5.7Quality: 5.5
Piotroski: 4/9Altman Z: 2.40

SRXH

Avoid

19

out of 100

Grade: F

Growth: 2.7Profit: 3.0Value: 5.0Quality: 4.0
Piotroski: 2/9Altman Z: -4.74
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

JBSSignificantly Overvalued (-132.0%)

Margin of Safety

-132.0%

Fair Value

$7.00

Current Price

$15.75

$8.75 premium

UndervaluedFair: $7.00Overvalued

Intrinsic value data unavailable for SRXH.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JBS3 strengths · Avg: 8.3/10
Return on EquityProfitability
24.1%9/10

Every $100 of equity generates 24 in profit

P/E RatioValuation
13.8x8/10

Attractively priced relative to earnings

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

SRXH0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

JBS3 concerns · Avg: 2.0/10
Profit MarginProfitability
2.5%3/10

2.5% margin — thin

EPS GrowthGrowth
-16.2%2/10

Earnings declined 16.2%

Debt/EquityHealth
2.561/10

Elevated debt levels

SRXH4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$36.08M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : JBS

The strongest argument for JBS centers on Return on Equity, P/E Ratio, Price/Book. Revenue growth of 13.4% demonstrates continued momentum.

Bull Case : SRXH

SRXH has a balanced fundamental profile.

Bear Case : JBS

The primary concerns for JBS are Profit Margin, EPS Growth, Debt/Equity. Debt-to-equity of 2.56 is elevated, increasing financial risk. Thin 2.5% margins leave little buffer for downturns.

Bear Case : SRXH

The primary concerns for SRXH are EPS Growth, Market Cap, Return on Equity. Debt-to-equity of 10.99 is elevated, increasing financial risk.

Key Dynamics to Monitor

JBS is growing revenue faster at 13.4% — sustainability is the question.

JBS generates stronger free cash flow (543M), providing more financial flexibility.

Monitor PACKAGED FOODS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

JBS scores higher overall (51/100 vs 19/100) and 13.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

JBS N.V.

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

JBS N.V., is a protein and food company globally. The company is headquartered in Amstelveen, Netherlands.

SRx Health Solutions Inc.

CONSUMER DEFENSIVE · PACKAGED FOODS · USA

SRx Health Solutions Inc. provides healthcare and medical treatment services.

Visit Website →

Want to dig deeper into these stocks?